title: From clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancer.
abstract: Therapeutic options for patients with metastatic castration-resistant prostate cancer are increasing, spurring an urgent need to better understand which treatments are best for individual patients. The recent approval of a first-in-class agent, sipuleucel-T, has intensified this need. This therapeutic cancer vaccine has demonstrated a survival advantage in two Phase III trials, but does not alter progression in the short term. Therefore, a new therapeutic approach for patients with metastatic castration-resistant prostate cancer is taking shape, based on broader understanding of available therapies. This new clinical approach seeks to maximize patient benefit from treatment, minimize associated toxicities, and may have far-reaching implications for other therapeutic cancer vaccines currently in clinical development.
authors.affiliation: Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20912, USA.
authors.forename: Ravi A
authors.initials: RA
authors.lastname: Madan
authors.forename: Jeanny B
authors.initials: JB
authors.lastname: Aragon-Ching
authors.forename: James L
authors.initials: JL
authors.lastname: Gulley
authors.forename: William L
authors.initials: WL
authors.lastname: Dahut
mesh_terms: D019496:Cancer Vaccines / Q000008:administration & dosage / Q000276:immunology; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis / Q000276:immunology* / Q000628:therapy*; D011471:Prostatic Neoplasms / Q000276:immunology* / Q000556:secondary / Q000628:therapy*; D016019:Survival Analysis; D014020:Tissue Extracts / Q000008:administration & dosage* / Q000276:immunology*; D016896:Treatment Outcome
chemical_list: D019496:Cancer Vaccines; D014020:Tissue Extracts; C511774:sipuleucel-T